These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

951 related articles for article (PubMed ID: 32385143)

  • 1. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
    Finckh A; Tellenbach C; Herzog L; Scherer A; Moeller B; Ciurea A; von Muehlenen I; Gabay C; Kyburz D; Brulhart L; Müller R; Hasler P; Zufferey P;
    RMD Open; 2020 May; 6(1):. PubMed ID: 32385143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study.
    Pappas DA; St John G; Etzel CJ; Fiore S; Blachley T; Kimura T; Punekar R; Emeanuru K; Choi J; Boklage S; Kremer JM
    Ann Rheum Dis; 2021 Jan; 80(1):96-102. PubMed ID: 32719038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
    Wadström H; Frisell T; Askling J;
    JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy.
    Amstad A; Papagiannoulis E; Scherer A; Rubbert-Roth A; Finckh A; Mueller R; Dudler J; Möller B; Villiger PM; Schulz MMP; Kyburz D
    Rheumatology (Oxford); 2022 Dec; 62(1):89-97. PubMed ID: 35579338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of drug survival for biologic and targeted synthetic DMARDs in rheumatoid arthritis: Analysis from the TRA Clinical Electronic Registry.
    Lin CT; Huang WN; Tsai WC; Chen JP; Hung WT; Hsieh TY; Chen HH; Hsieh CW; Lai KL; Tang KT; Tseng CW; Chen DY; Chen YH; Chen YM
    PLoS One; 2021; 16(4):e0250877. PubMed ID: 33930048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study.
    Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Takeuchi T; Nagai K; Son Y; Amuro H; Onishi A; Jinno S; Hara R; Katayama M; Yamamoto K; Kumanogoh A; Hirao M
    Clin Rheumatol; 2020 Sep; 39(9):2563-2572. PubMed ID: 32162152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis.
    Lauper K; Mongin D; Iannone F; Kristianslund EK; Kvien TK; Nordström DC; Pavelka K; Pombo-Suarez M; Rotar Z; Santos MJ; Codreanu C; Lukina G; Gale SL; John M; Luder Y; Courvoisier DS; Gabay C
    Semin Arthritis Rheum; 2020 Feb; 50(1):17-24. PubMed ID: 31280937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of baricitinib and alternative biological DMARDs in a Swiss cohort study of patients with RA.
    Gilbert BTP; Mongin D; Aymon R; Lauper K; Laedermann C; Perrier C; Mueller R; Courvoisier DS; Finckh A
    BMJ Open; 2024 Mar; 14(3):e072300. PubMed ID: 38479734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration.
    Lauper K; Nordström DC; Pavelka K; Hernández MV; Kvien TK; Kristianslund EK; Santos MJ; Rotar Ž; Iannone F; Codreanu C; Lukina G; Gale SL; Sarsour K; Luder Y; Courvoisier DS; Gabay C
    Ann Rheum Dis; 2018 Sep; 77(9):1276-1282. PubMed ID: 29730637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
    Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
    BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.
    Frisell T; Baecklund E; Bengtsson K; Di Giuseppe D; Forsblad-d'Elia H; Askling J;
    Ann Rheum Dis; 2018 May; 77(5):650-657. PubMed ID: 29237621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study).
    Aymon R; Mongin D; Bergstra SA; Choquette D; Codreanu C; De Cock D; Dreyer L; Elkayam O; Huschek D; Hyrich KL; Iannone F; Inanc N; Kearsley-Fleet L; Koca SS; Kvien TK; Leeb BF; Lukina G; Nordström DC; Pavelka K; Pombo-Suarez M; Rodrigues A; Rotar Z; Strangfeld A; Verschueren P; Westermann R; Zavada J; Courvoisier DS; Finckh A; Lauper K
    Ann Rheum Dis; 2024 Mar; 83(4):421-428. PubMed ID: 38071508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry.
    Choquette D; Bessette L; Alemao E; Haraoui B; Postema R; Raynauld JP; Coupal L
    Arthritis Res Ther; 2019 Jun; 21(1):138. PubMed ID: 31171024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
    Vieira MC; Zwillich SH; Jansen JP; Smiechowski B; Spurden D; Wallenstein GV
    Clin Ther; 2016 Dec; 38(12):2628-2641.e5. PubMed ID: 27889300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis.
    Kerschbaumer A; Sepriano A; Smolen JS; van der Heijde D; Dougados M; van Vollenhoven R; McInnes IB; Bijlsma JWJ; Burmester GR; de Wit M; Falzon L; Landewé R
    Ann Rheum Dis; 2020 Jun; 79(6):744-759. PubMed ID: 32033937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Most Appropriate Conventional Disease-Modifying Antirheumatic Drug to Combine With Different Advanced Therapies in Rheumatoid Arthritis: A Systematic Literature Review With Meta-Analysis.
    Decarriere G; Barnetche T; Combe B; Gaujoux-Viala C; Lukas C; Morel J; Daien C
    Arthritis Care Res (Hoboken); 2021 Jun; 73(6):873-884. PubMed ID: 32216091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
    Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
    Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence of bDMARD therapy in Rheumatoid Arthritis after first-line TNF-inhibitor failure: the RECORD study of the Italian Society for Rheumatology.
    Carrara G; Argnani L; Zanetti A; Zabotti A; Silvagni E; Sebastiani GD; Sebastiani M; Scirè CA
    Scand J Rheumatol; 2022 Sep; 51(5):363-367. PubMed ID: 35023421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in Market Share of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs for Treatment of Rheumatoid Arthritis: Results from the Ontario Best-Practice Research Initiative Database.
    Hepworth E; Movahedi M; Rampakakis E; Mirza R; Lau A; Cesta A; Pope J; Sampalis JS; Bombardier C
    Curr Rheumatol Rev; 2021; 17(3):349-359. PubMed ID: 33308132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted-synthetic therapy for the treatment of rheumatoid arthritis.
    Leong JWY; Cheung PP; Dissanayake S; Fong WWS; Leong KH; Leung YY; Lim AYN; Lui NL; Manghani M; Santosa A; Sriranganathan MK; Suresh E; Tan TC; Teng GG; Lahiri M
    Int J Rheum Dis; 2020 Feb; 23(2):140-152. PubMed ID: 31859424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.